Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Bioshares Biotech Summit 2025
22 slides from Amplia Therapeutics's conference presentation, Aug 7, 2025
Slide 1: ASX Release: Bioshares Biotech Summit Presentation
ABN 16 165 160 841 ASX RELEASE 7 August 2025 Bioshares Biotech Summit Presentation – Targeting Pancreatic Cancer and Beyond Amplia Therapeutics Limited (“ATX” or “the Company”) releases its Bioshares Biotech Summit Presentation which Managing Director Dr Chris Burns will present at the Bioshares Bio
Slide 2: Targeting Pancreatic Cancer and Beyond
For personal use only TARGETING PANCREATIC CANCER AND BEYOND August 2025 ampliatx.com | @ampliatx 1
Slide 3: Disclaimer
DISCLAIMER This presentation (Presentation) contains summary information about Amplia Therapeutics market, regulatory and other relevant environments that will exist and affect Amplia’s business and Limited ACN 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 30 operat
Slide 4: Executive Summary
EXECUTIVE SUMMARY Developing a pipeline of small molecule inhibitors of FAK Lead drug narmafotinib is best-in-class FAK inhibitor in development For personal use only Promising efficacy, durability and tolerability in Phase 2a ACCENT clinical trial in pancreatic cancer US trial of narmafotinib in pa
Slide 5: Metastatic Pancreatic Cancer
METASTATIC PANCREATIC CANCER Limited treatment options; poor patient outcomes 5Y Survival Limited Treatment Options Median Progression Median Overall Treatment Tolerability For personal use only Free Survival Survival Gemcitabine + Abraxane ® 5.5 months 8.5 months 3% (MPACT study) FOLFIRINOX 6.4 mon
Slide 6: The Amplia Advantage
THE AMPLIA ADVANTAGE Three critical features For personal use only Efficacy Narmafotinib Tolerability Durability 5
Slide 7: ACCENT Trial in mPDAC
ACCENT TRIAL IN mPDAC Phase 1b/2a study in Australia and Korea Intermittent dosing schedule OBJECTIVE narmafotinib To determine safety and efficacy of narmafotinib Gemcitabine + For personal use only when added to standard of care Abraxane in newly diagnosed patients PRIMARY ENDPOINTS Safety, Tolera
Slide 8: Interim Data: Progression Free Survival
ACCENT TRIAL INTERIM DATA Promising evidence of efficacy, durability and tolerability All ACCENT patients @ 400 mg (n = 64) Progression Free Survival (PFS) data For personal use only Currently determined at 7.6 months - substantially better than chemotherapy alone (5.5 months) Improvement over FOLFI
Slide 9: Interim Data: Confirmed Responses
ACCENT TRIAL INTERIM DATA Promising evidence of efficacy, durability and tolerability 17 confirmed responses observed to date For personal use only Includes: 1 confirmed complete response 1 pathological complete response Individual Patients Indicating narmafotinib + chemotherapy is superior to chemo
Slide 10: Interim Data: Response Rate
ACCENT TRIAL INTERIM DATA Promising evidence of efficacy, durability and tolerability Excellent response rate observed 1 confirmed Complete Response For personal use only 16 confirmed Partial Responses Incl. 1 patient determined to be a pathological Complete Response Objective response rate (ORR) of
Slide 11: Interim Data: Response Rate vs MPACT
ACCENT TRIAL INTERIM DATA Promising evidence of efficacy, durability and tolerability Excellent response rate observed ACCENT Trial MPACT Trial 1 confirmed Complete Response (Narmafotinib/Gemcitabine/Abraxane) (Gemcitabine/Abraxane) For personal use only 16 confirmed Partial Responses CR 2% 0.2% Inc
Slide 12: Interim Data: Durability
ACCENT TRIAL INTERIM DATA Promising evidence of efficacy, durability and tolerability Excellent durability observed For personal use only PD SD PR Interim data based on data cut-off Jul 20, 2025. Responses are investigator read 11
Slide 13: Interim Data: Tolerability
ACCENT TRIAL INTERIM DATA Promising evidence of efficacy, durability and tolerability Excellent tolerability observed to date Narmafotinib treatment results in negligible extra patient burden For personal use only Adverse Events (Grade 3 or above) Narmafotinib +Gem/Abr Gem/Abr Gem/Abr FOLFIRINOX NAL
Slide 14: Summary: On Track to Achieve Trial Goals
ACCENT TRIAL SUMMARY On track to achieve trial goals Superior Efficacy Improved Durability Demonstrated Tolerability For personal use only For full 55 patient cohort 7 patients on trial for >12 Excellent tolerability profile 1 CR months 16 PR Minimal additional burden on Deep and sustained response
Slide 15: Future Opportunities
FUTURE OPPORTUNITIES FAK inhibition will enhance multiple therapeutic strategies Narmafotinib (FAK inhibition) For personal use only CHEMOTHERAPY IMMUNOTHERAPIES Clinical and preclinical data incl. Preclinical data ACCENT study KRAS INHIBITORS RADIOTHERAPY Preclinical data, incl. Published data coll
Slide 16: AMPLICITY Trial in mPDAC
AMPLICITY TRIAL in mPDAC Phase 1b/2a study in the US and Australia Moving from intermittent to daily dosing OBJECTIVE To determine safety and efficacy of narmafotinib For personal use only narmafotinib when added to FOLFIRINOX in newly diagnosed patients FOLFIRINOX To identify recommended phase 2 do
Slide 17: Narmafotinib: A Potent and Selective FAK Inhibitor
NARMAFOTINIB: A POTENT AND SELECTIVE FAK INHIBITOR FAK enzyme overactive in pancreatic cancer Benefits of FAK Inhibition For personal use only Anti-proliferative Synergy with FAK levels are elevated in pancreatic cancer Reduces cells’ ability chemotherapies Correlate with worse patient outcome to pr
Slide 18: Narmafotinib: A Potent and Selective FAK Inhibitor
NARMAFOTINIB: A POTENT AND SELECTIVE FAK INHIBITOR FAK enzyme overactive in pancreatic cancer Benefits of FAK Inhibition For personal use only Anti-proliferative Synergy with FAK levels are elevated in pancreatic cancer Reduces cells’ ability chemotherapies Correlate with worse patient outcome to pr
Slide 19: Narmafotinib: Best-in-class Profile
NARMAFOTINIB: A POTENT AND SELECTIVE FAK INHIBITOR Best-in-class profile For personal use only Convenient to take Once a day oral dosing by capsule Storage at room temperature Safe to combine with other medicines No evidence of drug-drug interactions Evidence of FAK target engagement in humans 18
Slide 20: Upcoming Milestones
UPCOMING MILESTONES For personal use only Q3 2025 Q4 2025 Q1 2026 Q2 2026 2H 2026 ACCENT top-line data ACCENT further patient ACCENT mature data ACCENT trial completion ACCENT full data release updates (including OS) ACCENT request FDA type AMPLICITY further AMPLICITY 2-dose comparison trial C meeti
Slide 21: Board + Management
BOARD + MANAGEMENT World-class experts BOARD SENIOR MANAGEMENT For personal use only Rhiannon Jones PhD GAICD COO Warwick Tong Robert Peach Jane Bell Chris Burns MB ChB MPP GAICD PhD LLB LLM (Lond) FAICD PhD GAICD Director CEO and MD Jason Lickliter Chair Director MBBS FRACP CMO Tim Luscombe BCom CA
Slide 22: Thank You
For personal use only THANK YOU Chris Burns PhD GAICD FAHMS Rhiannon Jones PhD GAICD CEO and MD COO chris@ampliatx.com rhiannon@ampliatx.com Amplia Therapeutics Limited ASX: ATX info@ampliatx.com ampliatx.com 21